Argá Medtech, a company based in Lausanne, Switzerland, and San Diego, is planning to assess a new second generation pulsed field ablation system in patients with paroxysmal and persistent atrial fibrillation as part of the process to secure FDA approval. The system, known as the Coherent Sine-Burst Electroporation™, is targeted towards treating these heart conditions. The evaluation is expected to commence on September 18, 2025. This development signifies a significant step in the advancement of medical technology and treatment options for individuals with atrial fibrillation.